ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO219

Serum Fibroblast Growth Factor 21 Level Is a Risk Factor for Central Arterial Stiffness in Maintenance Hemodialysis Patients

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Chiu, Liang-Te, Buddhist Tzu Chi General Hospital, Hualien, Select a state/province, Taiwan
  • Lin, Lin, Buddhist Tzu Chi General Hospital, Hualien, Select a state/province, Taiwan
  • Hsu, Bang-Gee, Buddhist Tzu Chi General Hospital, Hualien, Select a state/province, Taiwan
Background

Fibroblast growth factor 21 (FGF21) is a hepatic hormone in the regulation of glucose and lipid metabolism. Serum FGF21 levels were higher in patients with carotid atherosclerosis and in patients with coronary artery disease. The aim of this study was to evaluate the relationship between serum FGF21 levels and carotid-femoral pulse wave velocity (cfPWV) values in patients on hemodialysis (HD).

Methods

Blood samples and baseline characteristics were obtained from 130 HD patients. Serum FGF21 concentrations were determined by enzyme-linked immunosorbent assay kit. Central arterial stiffness was defined as carotid-femoral pulse wave velocity (cfPWV) values >10 m/s according to the ESH-ESC 2013 guidelines.

Results

Among 130 HD patients, 54 patients (41.5%) were in the central arterial stiffness group. When compared to those in control group, the central arterial stiffness group had high prevalence of diabetes mellitus (P < 0.001), hypertension (P = 0.026), and older age (P = 0.036), higher body weight (P = 0.027), body mass index (P = 0.048), systolic blood pressure (P = 0.044), C-reactive protein (P = 0.040), and higher serum FGF21 level (P < 0.001). Multivariable logistic regression analysis of the factors significantly associated with central arterial stiffness revealed that FGF21 levels (odds ratio (OR): 1.001, 95% confidence interval (CI): 1.000–1.001, P = 0.001), age (OR: 1.043, 95% CI: 1.002–1.085, P = 0.042), and diabetes mellitus (OR: 4.495, 95% CI: 1.703–11.867, P = 0.002) were the independent predictors of central arterial stiffness in HD patients. Multivariable forward stepwise linear regression analysis also showed that logarithmically transformed FGF21 level (log-FGF21, β = 0.301, adjusted R2 change = 0.105, P < 0.001) was an independent predictor of cfPWV values in HD patients. The area under the receiver-operating characteristic (ROC) curve predicting central arterial stiffness by serum FGF21 level in HD patients was 0.693 (95% CI: 0.606-0.771, P < 0.001).

Conclusion

Serum FGF21 level positively correlated with cfPWV values and is also the independent predictor of central arterial stiffness among HD patients.